LEAMINGTON SPA, England,
October 4, 2010 /PRNewswire/ --
Hospira (NYSE: HSP), a global specialty pharmaceutical and
medication delivery company, announced today that Svend Andersen has been named corporate vice
president and president, Europe,
Middle East and Africa (EMEA). In this capacity, he will be
responsible for developing strategy, delivering growth and
attaining market leadership in the EMEA region. Andersen, 48, will
report to Ron Squarer, senior vice president and chief commercial
officer, effective Nov. 1, 2010.
"Svend is an accomplished, dynamic and ambitious business leader
who brings global experience in driving profitable growth and
creating value within the generics and branded pharmaceuticals
spaces," Squarer said. "In his more than 20 years in the healthcare
industry, he has compiled a strong track record of introducing new
products, developing markets and building teams, all of which will
be essential as Hospira takes on new opportunities and grows its
current business in the EMEA."
Under Andersen's leadership, Hospira will advance its EMEA
strategy, which includes expanding the company's geographic
footprint, growing its leading position in generic injectable
pharmaceuticals and biosimilars, and increasing market share in
infusion devices and consumables. Sales in the EMEA comprised 14
percent of Hospira's total sales in 2009.
Most recently, Andersen served as executive vice president,
Western Europe, at Actavis, the
world's fifth largest generic specialty pharmaceutical company.
There, he drove significant growth in the company's hospital
business, led five acquisitions, opened subsidiaries in six
European countries and, in 2009, launched over 300 products and
brands. He led the regional expansion from eight to 15 markets, and
bolstered the company's positions in the United Kingdom, Germany, Benelux and the Nordic countries. He
also was responsible for commercial operations, finance, supply,
regulatory and business development, with oversight of legal and
intellectual property.
Prior to joining Actavis, Andersen was vice president, general
manager at Alpharma, a global specialty pharmaceutical company,
where he directed strategy, restructured the organisation and
revitalised the business prior to its acquisition by Actavis. He
has also served as vice president, commercial operations, at
Ferrosan, a consumer healthcare and medical devices company, and
worked as a business consultant to four start-up companies.
Andersen earned his Bachelor of Science in Economic Sciences and
degrees in International Marketing; Organisational Behaviours and
Strategic Planning; and Advanced Advertising, all at Copenhagen
Business School.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness(TM). As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake
Forest, Ill., and has more than 13,500 employees. The head
office for Hospira in Europe,
Middle East and Africa is in Leamington Spa, UK. Learn more at
http://www.hospira.com.